Polylactide nanoparticles

Details Polylactide nanoparticles Polylactide nanoparticles

2011-08-23

2011-08-23

Wax, Robert A (Department: 1615)

Drug, bio-affecting and body treating compositions

Preparations characterized by special physical form

Particulate form

Reexamination Certificate

active

08003128

ABSTRACT:
A drug targeting system for administering a pharmacologically active substance to the central nervous system of a mammal across the animal's blood brain barrier. The drug targeting system comprises nanoparticles made of poly(DL-lactide) and/or poly(DL-lactide-co-glycolide), a pharmacologically active substance which is absorbed to, adsorbed to, and/or incorporated into the nanoparticles, and either contains TPGS or comprises a pluronic 188 surfactant coating deposited on the drug-loaded nanoparticles.

REFERENCES:
patent: 6117454 (2000-09-01), Kreuter et al.
patent: 6309663 (2001-10-01), Patel et al.
patent: 2005/0084456 (2005-04-01), Tang et al.
patent: 2005/0112188 (2005-05-01), Eliaz et al.
patent: 2006/0024248 (2006-02-01), Spengler et al.
patent: 2006/0141025 (2006-06-01), Huang et al.
patent: 1795185 (2007-06-01), None
patent: WO 9856361 (1998-12-01), None
patent: WO 2004/084871 (2004-10-01), None
patent: WO 2004/112695 (2004-12-01), None
Mu et al “A novel controlled release formulation of the anticancer drug paclitaxel (Taxol): PLGA nanoparticles containing vitamin E TPGS” Journal of Controlled Release 86 (2003) p. 33-48.
Dintaman, Jay M., et al.; “Inhibition of P-glycoprotein by d-alpha-tocopheryl polyethylene glycol 1000 succinate (TPGS);”Pharmaceutical Research, vol. 16, No. 10; Oct. 1999 (pp. 1550-1556).
Feng, S-S, et al; “Chemotherapeutic engineering: Application and further development of chemical engineering principles for chemotherapy of cancer and other diseases;”Chemical Engineering Science; vol. 58, No. 18; Sep. 2003 (pp. 4087-4114).
Muller, R.H., et al.; “Surface modification of i.v. injectable biodegradable nanoparticles with poloxamer polymers and poloxamine 908;”International Journal of Pharmaceutics; vol. 89, No. 1; 1993 (pp. 25-31).
Mu, et al.; “Application of TPGS in polymeric nanoparticulate drug delivery system;”Colloids and Surfaces.; vol. 47, No. 1; Jan. 15, 2006 (pp. 90-97).
Mu, et al.; “Vitamin E TPGS used as emulsifier in the solvent evaporation / extraction technique for fabrication of polymeric nanospheres for controlled release of paclitaxel;”Journal of Controlled Release.; vol. 80, No. 1-3; Apr. 23, 2002 (pp. 129-144).
Redhead, H.M., et al.; “Drug Delivery in poly(lactide-co-glycolide) nanoparticles surface modified with poloxamer 407 and poloxamine 908: In vitro characterisation and in vivo evaluation;”Journal of Controlled Release; vol. 70, No. 3; Feb. 23, 2001; (pp. 353-363).
Ruan, G, et al.; “Effects of material hydrophobicity on physical properties of polymeric microspheres formed by double emulsion process;”Journal of Controlled Release; vol. 84, No. 3; Dec. 5, 2002 (pp. 151-160).
Yoon, Jeong Park, et al.; “Surface-modified poly (lactide-co-glycolide) nanospheres for targeted bone imaging with enhanced labelling and delivery of radioisotope;”Journal of Biomedical Materials Research; vol. 67A, No. 3; 2003 (pp. 751-760).
Zhang, et al.; “Nanoparticles of poly(lactide)/vitamin E TPGS copolymer for Cancer Chemotherapy: Synthesis, formulation, characterization and in vitro drug release;”Biomaterials; vol. 27, No. 2; Jan. 2006 (pp. 262-270).
Mueller, R.H., et al.; “Surface modification of i.v. injectable biodegradable nanoparticles with poloxamer polymers and poloxamine 908;”International Journal of Pharmaceutics; vol. 89, No. 1; 1993 (pp. 25-31).

Affiliated with

Also associated with

Rating

Polylactide nanoparticles does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Polylactide nanoparticles, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Polylactide nanoparticles will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2784564